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and biotechnological applications 
Margaret McAuleya, Noel Mesa-Torresb, Aisling McFalla, Sarah Morrisa, Meilan Huangc, Angel L. Peyb 
and David J. Timsona,d,* 
 
Abstract: Galactokinase catalyses the site- and stereospecific 
phosphorylation of α-D-galactose.  As such it has attracted interest as 
a biocatalyst for the introduction of phosphate groups into 
monosaccharides.  However, attempts to broaden the substrate range 
of human galactokinase have generally resulted in substantially 
reduced activity.  The enzyme also has biotechnological potential in 
enzyme replacement therapy (ERT) for type II galactosemia.  The 
return-to-consensus approach can be used to identify residues which 
can be altered to increase protein stability and enzyme activity.  This 
approach identified six residues of potential interest in human 
galactokinase.  Some of the single consensus variants increased the 
catalytic turnover of the enzyme (M60V, D268E, A334S and G373S), 
but none resulted in improved stability.  When all six changes were 
introduced into the protein 
(M60V/M180V/D268E/A334S/R366Q/G373S) thermal stability was 
increased.  Molecular dynamics simulations suggested that these 
changes altered the protein’s conformation at key sites.  The number 
of salt bridges and hydrogen bonds was also increased.  Combining 
the six consensus variations with Y379W (a variant with greater 
substrate promiscuity) increased the stability of this variant and its 
turnover towards some substrates.  Thus, the six consensus variants 
can be used to stabilise catalytically interesting variants of human 
galactokinase and may also be useful if the protein were to be used 
in ERT. 
 
Introduction 
Galactokinase (GALK1; EC 2.7.1.6) catalyses the ATP-
dependent site- and stereo-specific phosphorylation of 
the hexose monosaccharide galactose [1].  
Physiologically, this reaction is required as the first 
committed step of the Leloir pathway of galactose 
metabolism [2].  This reaction converts galactose (which 
cannot be efficiently phosphorylated by the first 
enzyme of glycolysis, hexokinase) to galactose 1-
phosphate.  This compound subsequently reacts with 
UDP-glucose, generating UDP-galactose and glucose 1-
phosphate in a reaction catalysed by galactose 1-
phosphate uridylyltransferase.  Glucose 1-phosphate is 
isomerised to glucose 6-phosphate, a glycolytic 
intermediate by phsophoglucomutase.  UDP-glucose is 
regenerated from UDP-galactose by the action of UDP-
galactose 4’-epimerase.  The Leloir pathway also has a 
role in maintaining the pools of UDP-sugars which are 
used in the biosynthesis of glycoproteins and 
glycolipids. 
Sugar 1-phosphates are useful precursors in the 
chemical synthesis of more complex molecules which 
contain monosaccharide moieties, including 
aminoglycoside antibiotics [3].  Although 
phosphorylation of monosaccharides can be achieved 
chemically using reagents such as phosphoric acid, the 
presence of multiple hydroxyl groups means that a 
wide range of products are normally produced.  
Consequently, enzymes such as galactokinase which 
catalyse the site-specific phosphorylation of 
monosaccharides are of interest in biocatalysis [4]. 
Galactokinase demonstrates high selectivity, catalysing 
the phosphorylation of the hydroxyl group at position 
1 in the α-anomeric configuration only.  The human 
enzyme is also highly specific for its sugar substrate:  α-
D-galactose and the closely related sugars α-D-
galactosamine and 2-deoxy-α-D-galactose are the only 
known substrates of the wild-type enzyme [5].  In 
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general, bacterial galactokinases seem to have more 
relaxed specificity, both in terms of the range of 
substrates and the sites which can be phosphorylated; 
however the substrate range is still limited [6].  
Considerable efforts have been made to expand the 
substrate range of Escherichia coli and Lactococcus 
lactis galactokinases.  A combination of rational and 
random mutagenesis has identified two sites in 
bacterial galactokinases (Met-173 and Tyr-371 in the E. 
coli enzyme) which, when altered, greatly broaden the 
substrate range of these enzymes [6a, 7].  Parallel studies 
have also been conducted using the human enzyme.  
Alteration of the equivalent tyrosine residue (Tyr-379) 
also broadens the specificity range of the enzyme, 
albeit with considerable reduction in activity [8].  This 
tyrosine residue forms part of a β-sheet structure 
which is distant from the active site [9].  It has been 
postulated that alteration of the tyrosine residue 
results in changes to the dynamics of active site 
residues which enable a greater range of molecules to 
bind, but also reduces catalytic efficiency [8, 10]. 
Galactokinase is also implicated in human disease [11].  
Mutations in the gene encoding human galactokinase 
are associated with the inherited metabolic disease 
type II galactosemia (OMIM #230250) [11b, 12].  
Compared to types I and III galactosemia, type II is 
generally considered relatively mild [13].  The only well-
documented manifestations of this disease are early 
onset cataracts which can be resolved by elimination of 
galactose (and its precursors such as lactose) from the 
diet or by surgery [14].  However, some reports suggest 
that there may be more serious, long term 
consequences of this disease including mental 
retardation and failure to thrive, especially where 
dietary compliance has been poor [15].  Other than 
dietary restriction of galactose, no other treatments 
are available for type II galactosemia.  Some inherited 
metabolic diseases can be treated by enzyme 
replacement therapy (ERT).  This treatment involves 
the supplementation with highly purified, recombinant 
enzyme [16].  A common problem in ERT is short protein 
half-lives in the plasma or in cells. 
More structurally robust forms of galactokinase would 
have advantages in biocatalysis.  Such modified forms 
of the enzyme would be more likely to withstand 
increased temperatures and also to remain active over 
longer periods.  If ERT was considered desirable and 
viable for the treatment of type II galactosemia, then 
more stable forms of the enzyme may be desirable.  
One method for improving the overall stability of 
proteins is the so-called consensus approach.  This 
involves identification (through sequence alignments) 
of residues which deviate from the consensus in a 
target sequence (e.g. the human orthologue).  These 
deviations are likely to result from natural changes in 
gene sequences over evolutionary timescales.  Such 
changes will be tolerated so long as they do not 
damage the overall fitness of the organism.  Altering 
the affected residues back to the consensus often 
results in increased overall protein stability and, 
sometimes, enhanced activity [17]. This approach is also 
useful to identify second-site suppressors of disease 
phenotypes [18].  Here we report the identification of six 
sites in human galactokinase which deviate from the 
consensus and the effects of restoring the consensus 
on the stability and activity of the enzyme.  Molecular 
dynamics simulations were used to help understand 
the mechanisms of any changes in stability.  Some of 
the variants reported here have improved overall 
robustness and so may be valuable in the development 
of biocatalysts. 
Results and Discussion 
Identification of six key sites which deviate from the 
consensus in human galactokinase 
Consensus variants for human GALK1 were identified 
from the analysis of a sequence alignment of animal 
sequences (Supplementary Figure S2A). This analysis 
provided twelve different sites as potential consensus 
variants (Supplementary Figure S2B). Five variants 
(K69T, Q172K, V238E H363R and H371K) were 
discarded since similar analyses using only sequences 
from mammals revealed a high frequency of the 
human amino acid at these positions (Supplementary 
Figure S2B). The C391S variant was also discarded due 
to the appearance of 12 different amino acids (out of 
26 sequences at this position), indicating high 
degeneracy.  Therefore, a set of six consensus variants 
(M60V (2), M180V (3), D268E (4), A334S (5), R366Q (6) 
and G373S (7)) were selected for further experimental 
characterisation (Figure 1). 
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The six individual return-to-consensus variants were 
expressed in, and purified from, E. coli.  In addition, two 
double variants (M60V/M180V (8) and M60V/A334S 
(9)), one triple variant (M60V/M180V/A334S (10)), one 
quadruple variant (M60V/M180V/A334S/G373S (11)), 
one penta-variant 
(M60V/M180V/A334S/D268E/G373S (12)) and one 
hexa-variant incorporating all the return-to-consensus 
changes identified in this study 
(M60V/M180V/A334S/D268E/R336Q/G373S (13)) 
were synthesised.  All six proteins were in the soluble 
fraction following disruption of the bacterial cells by 
sonication (Supplementary Figure S3).  Typical yields 
were in the range 1-2 mg purified GALK1 per litre of 
bacterial cell culture.  
 
Figure 1. Location of the consensus residues identified in this study.  The 
structure of human galactokinase (PDB 1WUU [9]) is shown in grey.  The 
substrates (galactose and ATP) are shown in stick format and the consensus 
residues in space-filling format, highlighted in colour. 
Some individual return-to-consensus variants increase 
catalytic turnover, but none increase stability 
The six return-to-consensus variants were first tested 
individually.  Four of these (M60V (2), D268E (4), A334S 
(5) and G373S (7)) had statistically significantly 
increased catalytic turnover (kcat).  One (M180V (3)) 
had a significantly decreased turnover and one (R336Q 
(6)) was unchanged.  However, none of these changes 
were greater than three-fold.  (Table 1; Supplementary 
Figure S4).  In general, where there was an increase in 
the turnover number, there was a corresponding 
increase in the Michaelis constants.  Consequently, 
there were no significant changes in the specificity 
constants for either galactose or ATP for any of these 
six variants. 
Two of these variants (D268E (4) and A334S (5)) caused 
a significant decrease in the thermal stability (Tm); the 
remainder had no significant effect (Table 2).  D268E 
(4) is also less stable towards chaotropic denaturation.  
In native gel electrophoresis, the wild-type protein ran 
largely as one band in the absence of urea.  This band 
was still detected (albeit at lower intensity) up to 2 M 
urea.  In contrast, D268E (4) in 0.5 M urea runs largely 
as a faster migrating form which is present up to 2 M 
urea (Figure 2). 
 
Figure 2. Stability of variant galactokinases to denaturation by the 
chaotropic agent, urea.  Enzymes (4.5 µM) enzyme were incubated at 37°C 
for 30 min with increasing concentrations of urea (shown above the gel) before 
loading onto a 15% native polyacrylamide gel (pH 8.8) and electrophoresed at 
20 mA for 3 h.  Proteins were visualised by staining with Coomassie blue.  In 
general, non-denatured proteins run as a darker band (sometimes with slower 
migrating species) which becomes more blurred and/or lighter as the urea 
concentration increases.  Variant galactokinases which become blurred/lighter 
at lower concentrations of urea are more susceptible to chaotropic denaturation. 
Met-180 
Met-60 
Asp-268 
Ala-334 
Gly-373 
Arg-336 
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Table 1. Kinetic parameters of consensus variants of human galactokinase 
All measurements taken using 70 nM enzyme as described in Materials and Methods.  Parameters were estimated by fitting graphs of Vmax.app plotted against substrate concentration with Michaelis-Menten equation 
using nonlinear curve fitting and errors shown are standard errors calculated in this process.  Significance calculated via one-way ANOVA with Dunnett’s post-test analysis to compare with the wild-type enzyme’s 
parameters.  * p≤0.05; ** p≤0.01; *** p≤0.001.
Entry 
number 
Galactokinase variant Km, ATP 
(µM) 
Km, Gal 
(µM) 
kcat  
(s-1) 
kcat /Km, ATP 
(mM-1s-1) 
kcat /Km,Gal 
(mM-1s-1) 
1 Wild type 3.9± 1.1 170 ± 25 1.7 ± 0.05 430 ± 108 10.1 ± 1.2 
2 M60V 18 ± 4.7** 220 ± 90 4.8 ± 0.3*** 270 ± 58 21.8 ± 7.5 
3 M180V 5.4 ± 0.84 99 ± 36 1.0 ± 0.03** 185 ± 27 10.1 ± 3.3 
4 D268E 13 ± 4.3* 580 ± 91** 3.2 ± 0.2*** 240 ± 68 6.0 ± 7.0 
5 A334S 7.9 ± 3.0 280 ± 98 4.3 ± 0.3*** 550 ± 188 15.4 ± 4.3 
6 R366Q 7.7 ± 4.2 530 ± 170* 2.1 ± 0.2 270 ± 130 4.0 ± 1.0 
7 G373S 13 ± 4.3* 90 ± 47 2.4 ± 0.2** 190 ± 56 25 ± 12* 
8 M60V/M180V 1.0 ± 0.3 190 ± 53 1.5 ± 0.02 1430 ± 410*** 8.8 ± 2.1 
9 M60V/A334S 4.2 ± 2.9 480 ± 180* 2.6 ± 0.01*** 620 ± 230 5.4 ± 1.5 
10 M60V/M180V/A334S 0.82 ± 1.60 78 ± 32 1.7 ± 0.04 2000 ± 240 20 ± 8 
11 M60V/M180V/A334S/G373S 0.57 ± 0.66 230 ± 70 1.7 ± 0.1 3000 ± 1000 7.3 ± 1.9 
12 M60V/M180V/A334S/D268E/G373S 2.5 ± 0.6 270 ± 103 1.7 ± 0.04 680 ± 141 6.3 ± 2.0 
13 M60V/M180V/A334S/D268E/R336Q/G373S 3.8 ± 0.6 150 ± 20 1.6 ± 0.05 390 ± 58 10.9 ± 1.3 
14 M185L 34.5 ± 6.3*** 1190 ± 270 8.1 ± 0.4*** 236 ± 34 8.0 ± 1.2 
15 Y379W 5.0 ± 0.7 1320 ± 430 6.8 ± 1.5** 1360 ± 180 5.2 ± 0.6 
16 M185L/Y379W 11.4 ± 2.9 1120 ± 400 2.5 ± 0.1 220 ± 50 2.4 ± 0.5* 
17 M60V/M180V/D268E/A334S/R366Q/G373S/Y379W 8.1 ± 1.8 310 ± 85 5.0 ± 0.3* 550± 110 16.1 ± 3.6 
18 M60V/M185L/M180V/D268E/A334S/R366Q/G373S/Y379W 12.4 ± 5.8 3278 ± 487*** 12.9 ± 0.9*** 1000 ± 350 3.9 ± 0.3 
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Molecular dynamics simulations of these variants 
revealed some interesting features when compared to 
the wild-type proteins.  In M60V (2), alterations were 
seen in a largely α-helical region (residues 232-240) 
which has previously been implicated in catalysis [19].  
Another key change was observed around residue 156, 
resulting in shortening of an α-helix and consequent 
displacement of residues 163-177 (Figure 3a).  Similar 
changes were seen in M180V (3), D268E (4) and A334S 
(5).  In M180V (3), residues 260-270 are also displaced 
and in A334S (5), a tighter turn around residues 257 
and 258 displaces a similar region (residues 262-270).  
R336Q (6) and G373S (7) showed fewer changes in 
residues 232-240 compared to the other four variants.  
A334S (5) and G373S (7) showed similar changes 
around residues 257-270.  The loop comprised of 
residues 257 and 258 is more flexible in R336Q (6).  In 
this variant, the effect is the displacement of residues 
261-264 and the lengthening of an α-helix (residues 
274-290).  M60V (2) has a predicted increase in the 
number of salt bridges and hydrogen bonds compared 
to the wild-type protein (Table 3).  However, these do 
not translate into increased thermal stability (Table 3). 
 
Figure 3. Molecular dynamics reveal changes in the protein’s 
conformation.  (a) A comparison of the wild-type protein (1) (yellow) and the 
M60V (2) variant (blue) showing predicted changes in two linked α-helices. (b) 
A comparison of the M60V (2) variant (orange) with the M60V/A334S (9) double 
variant showing two key regions which differ between the variants.  (c) Graphs 
showing the root mean square fluctuation (RMSF) for two regions in the vicinity 
of salt bridges predicted to form in the hexa-variant 
(M60V/M180V/A334S/G373S/D268E/R336Q (13); black circles) compared to 
the wild type (1) (red squares).  (d) A comparison of the wild-type protein (yellow) 
(1) and the Y379W variant (15) (green) showing two predicted structural 
changes. 
Combinations of return-to-consensus variants increase 
stability 
The greatest increase in turnover number was seen in 
the M60V (2) and A334S (5) variants.  Combining these 
two variants (M60V/A334S (9)) also resulted in a 
significant increase in the turnover number, but this 
increase was not as great as in M60V (2) alone (Table 
1; Supplementary Figure S4).  This double variant (9) 
had reduced stability towards thermal denaturation 
(Table 2).  Combining M60V and M180V (7) resulted in 
a modest, but significant increase in the melting 
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temperature, but no change in the turnover number 
(Tables 1, 2).  Interestingly, this was the only variant 
studied with a significantly increased (three-fold) 
specificity constant for ATP (Table 1).  When the three 
variants (M60V/M180V/A334S (10)) were combined, 
none of the steady state kinetic parameters were 
significantly altered.  However, this triple variant did 
have significantly increased thermal stability.  
Combining four (M60V/M180V/A334S/G373S (11)), 
five (M60V/M180V/A334S/G373S/D268E (12)) or six 
(M60V/M180V/A334S/G373S/D268E/R336Q (13)) 
variants resulted in a similar increase in thermal 
stability, but no significant change in the kinetic 
parameters (Tables 1, 2).  The combination of all six 
variants also appeared to result in a protein which was 
more stable towards denaturation by urea (Figure 2). 
Table 2. Thermal stability of galactokinase variants 
Entry 
number 
Variant Tm (°C) 
1 Wild type 55.74 ± 0.13 
2 M60V 55.93 ± 0.29ns 
3 M180V 55.17 ± 0.29ns 
4 D268E 52.31 ± 0.30*** 
5 A334S 54.41 ± 0.17* 
6 R366Q 55.81 ± 0.10ns 
7 G373S 55.01 ± 0.16ns 
8 M60V/M180V 57.7 ± 0.35*** 
9 A334S/M60V 52.31 ± 0.12*** 
10 M180V/M60V/A334S 58.08 ± 0.08*** 
11 M180V/M60V/A334S/G373S 58.11 ± 0.28*** 
12 M180V/M60V/A334S/G373S/D268E 58.09 ± 0.35*** 
13 M60V/M180V/A334S/D268E/R336Q/
G373S 
58.12 ± 0.50*** 
14 M185L 50.51 ± 0.34*** 
16 Y379W 52.07 ± 0.22*** 
16 M185L/Y379W 50.33 ± 0.71*** 
17 M60V/M180V/D268E/A334S/R366Q/
G373S/Y379W 
57.14 ± 0.35*** 
18 M60V/M185L/M180V/D268E/A334S/
R366Q/G373S/Y379W 
53.83 ± 0.87*** 
Melting temperature values (Tm) of variant galactokinases (4.5 µM) were 
determined by differential scanning flourimetry.  Significance was 
determined by comparing means of each dataset (n=9) to the wild-type 
value using one-way ANOVA.  ns, not significant; * p≤0.05; ** p≤0.01; *** 
p≤0.001. 
MD simulations showed that the M60V/A334S (9) and 
M60V/M180V (8) double variants are predicted to vary 
in the region 232-240 and also in the turn comprised of 
residues 173-181 which became tighter.  In 
M60V/A334S (9) an α-helix (residues 154-161) is also 
shortened (Figure 3b).  Interestingly, the changes to 
residues 154-161 and 173-181 were not observed in 
the triple variant (M60V/M180V/A334S (10)).  The 
quadruple variant (M60V/M180V/A334S/G373S (11)) 
showed all three changes as did the hexa-variant 
(M60V/M180V/A334S/G373S/D268E/R336Q (13)).  
The main changes observed in the penta-variant 
(M60V/M180V/A334S/G373S/D268E (12)) were in 
residues 173-181.  All of the multiple variants were 
predicted to have an increased number of salt bridges 
compared to wild-type and all except the hexa-variant 
were predicted to have an increased number of 
hydrogen bonds (Table 3).  Of particular interest, are 
the salt bridges between Glu245-Arg249 and Glu274-
Arg278.  These are predicted to occur in all the variants 
with increased thermal stability.  It seems likely that 
these residues contribute to the reduced flexibility 
around residue 270 resulting in increased global 
protein stability.  Analysis of the root mean squared 
fluctuation (RMSF) of these two regions showed that 
the first region had a reduction in the hexa variant (13) 
compared to the wild-type.  However, the second 
region did not (Figure 3c). 
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Table 3. Structural properties of the variant galactokinases predicted from 
molecular dynamics simulations 
The number of salt bridges present in each variant was calculated using 1 ns 
of stable trajectory and the ‘salt bridges’ plugin of VMD.  A 3.2 Å cut-off 
distance from oxygen to nitrogen was used.  Mean numbers of hydrogen 
bonds present in each consensus variant were calculated using a 1 ns 
trajectory of stable simulation using the ‘Hydrogen bonds’ plugin in VMD.  
Error values shown are the standard deviations. Significance was 
determined using a one-way ANOVA and significance compared to wild-
type determined using Dunnett’s post-test analysis. ns, not significant; * 
p≤0.05; *** p≤0.001. 
 
Consensus changes stabilise variants with altered 
catalytic properties 
In some bacterial galactokinases, alteration of a 
methionine residue to leucine increases the substrate 
range [7d].  The equivalent residue in the human enzyme 
is Met-185.  An M185L (14) variant of human 
galactokinase had statistically significantly increased 
catalytic turnover, with corresponding increases in the 
Michaelis constants for both substrates (all 
approximately 8 to 10-fold).  Consequently, the 
specificity constants for galactose and ATP were not 
significantly changed (Table 1).  This variant was 
significantly less thermally stable than the wild-type 
protein and was less resistant to denaturation by urea 
(Table 2; Figure 2).  An initial screen with 16 
monosaccharides did not reveal any novel substrates 
for the M185L variant (14) (data not shown) suggesting 
that this variant does not increase the promiscuity of 
the human enzyme.  This screen did reveal that, like the 
wild-type enzyme, the M185L variant (14) is active with 
2-deoxy-D-galactose and D-galactosamine.  In addition, 
the wild-type (1) and M185L variant protein (14) are 
both active with D-talose, a sugar which has not been 
tested previously as a substrate of human 
galactokinase (Table 4). 
 
It has been shown previously that alteration of Tyr-379 
can increase the substrate range of human 
galactokinase [8].  Of the alterations at Tyr-379, Y379W 
(15) was the most promiscuous, demonstrating activity 
with the greatest range of monosaccharide substrates 
[8].  MD studies predicted that this change disrupted the 
α-helix between residues 232 and 234 (Figure 3d).  
Similar changes were seen in the other variants at this 
site (data not shown).  In addition, a short section of α-
helix is created in Y379W (15) between residues 176 
and 179 (Figure 3d).  This is close to the active site and 
the catalytically important residue, Glu-174.  Like 
M185L (14), this variant is thermally destabilised 
compared to the wild-type (Table 2).  However, when 
combined with the six return-to-consensus variants 
(M60V/M180V/A334S/G373S/D268E/R336Q/Y379W 
(17)), the protein was significantly more thermally 
stable than the wild-type or Y379W alone (Table 2).  
This variant also had a modest decrease in turnover 
number for galactose (compared to Y379W (15)), but a 
three-fold increase in the catalytic efficiency (as 
reflected in the specificity constant) for galactose 
which results largely from the reduction in the 
Michaelis constant (Table 1).  Combining M185L and 
Y379W (M185L/Y379W (16)) did not result in an 
increase in the substrate range (data not shown).  The 
resulting protein had a four-fold decreased specificity 
constant for galactose (Table 1) and reduced thermal 
stability (Table 2) compared to the wild-type.  
However, it did have a significantly increased turnover 
and specificity constant for D-galactosamine (Table 4).  
Combining these two alterations with the six 
consensus changes (18) resulted in an enzyme with 
significantly increased (six-fold) turnover number for 
galactose (Table 1), but this effect did not occur with 2-
deoxy-D-galactose or D-galactosamine as substrates.  
However, the catalytic efficiency for galactose 
(kcatKm,gal) was reduced three-fold largely due to the  
Entry 
number 
Variant Number of 
predicted 
salt 
bridges 
Number of 
predicted 
hydrogen 
bonds 
1 Wild type 32 87.3 ± 7.4 
2 M60V 40 89.8 ± 
7.9*** 
3 M180V 31 86.3 ± 7.4* 
4 D268E 33 88.2 ± 7.6ns 
5 A334S 36 87.5 ± 7.3ns 
6 R366Q 38 87.3 ± 7.6ns 
7 G373S 36 88.1 ± 7.5ns 
8 M160V/M180V 40 89.1 ± 
7.8*** 
9 A334S/M60V 39 92.1 ± 
7.6*** 
10 M60V/M180V/A334S 37 90.8 ± 
7.5*** 
11 M60V/M180V/A334S 
/G373S 
33 89.2 ± 
7.5*** 
12 M60V/M180V/ 
D268E/A334S/G373S 
35 89.5 ± 
7.3*** 
13 M60V/M180V/ 
D268E/A334S/R366Q/G373S 
37 86.7 ± 7.3ns 
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Table 4. Kinetic parameters of selected variants with substrates other than galactose 
ENTRY 
NUMBER 
SUGAR VARIANT KM ATP 
(µM) 
KM SUGAR 
(µM) 
KCAT 
(S-1) 
KCAT /KM ATP (MM-1S-1) KCAT /KM SUGAR (MM-1S-1) 
1 2-DEOXY-D-GALACTOSE WILD-TYPE 43.2 ± 5.6 970 ± 130 6.8 ± 0.4 190 ± 10 7.1 ± 0.6 
14  M185L 17.3 ± 15.5* 7400 ± 7300 0.4 ± 0.1*** 23 ± 15** 0.06 ± 0.01*** 
15  Y379W 16.0 ± 3.6** 2200 ± 830 0.8 ± 0.1*** 50 ± 8* 0.39 ± 0.06*** 
17  M60V/M180V/D268E/A334S/R366Q/G37
3S/Y379W 
17.4 ± 6.0* 2000 ± 890 6.8 ± 0.1 390 ± 94** 3.1 ± 0.6*** 
18  M60V/M185L/M180V/D268E/A334S/R36
6Q/G373S/Y379W 
4.0 ± 4.0*** 300 ± 90 0.7 ± 0.1*** 19.4 ± 4.0 2.3± 0.5*** 
1 D-GALACTOSAMINE WILD-TYPE 16.2 ± 5.3 710 ± 180 1.7 ± 0.2 110 ± 25 2.9 ± 0.5 
15  Y379W 3.7 ± 0.8 220 ± 55 0.2 ± 0.0 50 ± 10 0.3 ± 0.1 
16  M185L/Y379W 2.7 ± 1.0 270 ± 54 25 ± 1*** 950 ± 310** 91 ± 14*** 
17  M60V/M180V/D268E/A334S/R366Q/G37
3S/Y379W 
6.6 ± 5.7 4800 ± 1000*** 4.0 ± 0.9 600 ± 420 0.9 ± 0.1 
18  M60V/M185L/M180V/D268E/A334S/R36
6Q/G373S/Y379W 
4.4 ± 1.8 620 ± 170 0.3 ± 0.0 67 ± 24 0.4 ± 0.1 
1 D-TALOSE WILD-TYPE 170 ± 86 370 ± 370 2.0 ± 0.7 110 ± 15 2.6 ± 0.8 
17  M60V/M180V/D268E/A334S/R366Q/G37
3S/Y379W 
13.4 ± 8.3* 2200 ± 780 0.2 ± 0.1* 17.6 ± 7.6 0.2 ± 0.02** 
All measurements taken using 70 nM enzyme as described in Materials and Methods.  Parameters were estimated by fitting graphs of Vmax.app plotted against substrate concentration with Michaelis-Menten equation 
using nonlinear curve fitting and errors shown are standard errors calculated in this process.  Significance calculated via one-way ANOVA with Dunnett’s post-test analysis to compare with the wild-type enzyme’s 
parameters.  * p≤0.05; ** p≤0.01; *** p≤0.001. 
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increase in the Michaelis constant (Table 4).  While its 
thermal stability is lower than the wild-type, it is higher 
than M185L/Y379W (16) (Table 2).  This demonstrates 
that the combination of six consensus variants can be 
used to increase the thermal stability (and, in some 
cases, the catalytic activity) of catalytically interesting 
forms of the enzyme.  However, it is interesting to note 
that the effects appear to be quite substrate-
dependent (compare Table 1 and Table 4). 
Conclusions 
The return-to-consensus variants identified in this 
study increase the stability of human galactokinase 
when combined together.  Thus, the consensus 
variants identified here are likely to be useful in the 
stabilisation of the broad specificity variants which may 
be discovered in future work.  Since the enzyme 
containing all six return-to-consensus variants (13) is 
more stable than the wild-type (1) without 
compromising the catalytic activity, this variant would 
have potential for the development of enzyme 
replacement therapies for type II galactosemia.  
Interestingly each individual variant has either no 
effect on, or reduces, the thermal stability 
demonstrating that the variants have synergistic 
effects on the protein’s structure.  These results are in 
contrast with those obtained with other proteins, in 
which the effect of consensus mutations’ effects on the 
stability and activity are often shown to be additive (i.e. 
single mutants have an effect, and the overall effect in 
a multiple mutant is essentially additive)[17a, 18a]. 
Interestingly, the opposite effect of multiple consensus 
mutations is found for GALK activity.  Some variants 
individually increased the turnover number of the 
enzyme, but combinations generally had little effect.  
Where turnover number was increased, this was 
generally accompanied by corresponding increases in 
the Michaelis constants.  Therefore, these variants 
would require higher concentrations of substrates in 
order to achieve the increased turnover.  The use of 
these variants in biocatalysis would be restricted to 
applications where high turnover was the priority and 
it was economically and chemically feasible to maintain 
high substrate concentrations.  The lack of additivity in 
the variants was surprising when compared to previous 
studies on consensus variants of other enzymes (e.g. 
[17a, 20]).  This currently remains unexplained, but we 
hypothesise that the high sensitivity of human 
galactokinase to variation may be part of the cause.  
We also observed poor correlation between increased 
stability (as judged by resistance to thermal or 
chaotropic denaturation) and increased catalytic 
turnover.  The mobility of enzymes is closely related to 
their catalytic properties [21] and it does not 
automatically follow that more stable proteins will be 
more active.  Too little flexibility at key sites may hinder 
activity.  Nevertheless, we propose that, based on this 
work, it may be possible to use the more stable variants 
as starting points for the identification of more 
catalytically active or promiscuous galactokinases. 
Molecular dynamics studies provide some partial 
explanations of the experimental data.  Two key salt 
bridges appear to be critical to the increased stability 
and further alternation of the four residues involved 
might also generate variants with altered stability.  The 
MD studies also re-emphasise the critical role of 
residues 232-240 on the structure, dynamics and 
catalytic activity of the enzyme.  We previously 
identified this as a critical region in the catalytic 
mechanism of the enzyme [19].  We hypothesise that 
direct alteration of these residues may affect the 
activity or specificity of the kinase.  In particular we 
propose that alterations designed to modulate 
flexibility of the protein in this region will impact on 
catalytic activity. 
Overall, the data presented here demonstrate that 
return-to-consensus variants of human galactokinase 
can improve the stability or the turnover of the 
enzyme.  Previous studies which have recapitulated 
disease-associated variants or have directly altered 
active site residues have often resulted in insoluble 
and/or inactive protein [5, 12b, 22].  While alteration of 
Tyr-379 did expand the substrate range of the enzyme, 
there were also substantial reductions in activity [8].  
The consensus approach opens up the possibility of 
designing new variants by introducing further changes 
into human galactokinase against the background of 
the six return-to-consensus variants.  This is more likely 
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to result in soluble protein with reasonable activity.  
Furthermore, a similar approach could be applied to 
bacterial galactokinases which appear to have 
naturally greater substrate ranges. 
Experimental Section 
Consensus analysis of human GALK1 
For consensus analyses, 25 protein sequences which were highly 
homologous to that of human GALK1 (P51570, NP_000145.1) belonging to 
animals were retrieved online using BLASTP and aligned using ClustalW [23]. 
This alignment of 26 sequences was used to identify consensus variants, as 
those that place the most common amino acid at a given position in the 
alignment (the consensus amino acid) instead of the human amino acid. 
 
Expression, purification and mutagenesis of human GALK1 
Recombinant human wild-type galactokinase was expressed in, and purified 
from, E. coli as previously described [19, 24].  For site-directed mutagenesis, 
the plasmid was mutated using the QuikChange method and the full 
sequence verified (GATC Biotech, London, UK) [25].  The resulting variant 
proteins were expressed and purified using the same methods as for the 
wild-type.  Purifications were monitored using SDS-PAGE. 
 
Galactokinase kinetics 
The rate of reaction was measured by coupling the production of ADP to the 
reactions catalysed by pyruvate kinase and lactate dehydrogenase [26].  This 
results in the stoichiometric consumption of one molecule of NADH for each 
sugar molecule phosphorylated, which can be monitored by measuring the 
decrease in absorbance at 340 nm.  Reactions were carried out in triplicate 
at 37 °C in 50 mM Hepes-OH buffer (pH 7.5) containing 150 mM NaCl, 5 mM 
MgCl2, 0.4 mM phosphoenolpyruvate, 1 mM NADH, 10%(v/v) glycerol, 
pyruvate kinase (7.5 U), lactate dehydrogenase (10 U) and varying, sub-
saturating amounts of ATP and galactose.  Enzyme (70 nM) was added to 
initiate the reaction which was monitored using a Thermo Scientific 
Multiskan Spectrum plate reader and the total reaction volume was 160 µl.  
Kinetic constants were determined by arraying reactions in an eight by ten 
grid in order to determine apparent Michaelis constants (Km,app) and 
apparent turnover numbers (kcat,app) over a range of sub-saturating 
concentrations of ATP and galactose using non-linear curve fitting to the 
Michealis-Menten equation as implemented in GraphPad Prism 6.0 
(GraphPad Software, CA, USA).  These were then used to determine the 
absolute values of the turnover number (kcat), the Michaelis constant for 
galactose (Km,gal) and the Michaelis constant for ATP (Km,ATP) as previously 
described [19, 27].  In brief, plots of kcat.app against substrate concentration 
were fitted using equations 1a and 1b to determine absolute values. 
𝑘𝑘𝑐𝑐𝑐𝑐𝑐𝑐,𝑐𝑐𝑎𝑎𝑎𝑎 = 𝑘𝑘𝑐𝑐𝑐𝑐𝑐𝑐[ATP]𝐾𝐾𝑚𝑚,𝐴𝐴𝐴𝐴𝐴𝐴+[ATP] (1a) 
𝑘𝑘𝑐𝑐𝑐𝑐𝑐𝑐,𝑐𝑐𝑎𝑎𝑎𝑎 = 𝑘𝑘𝑐𝑐𝑐𝑐𝑐𝑐[Galactose]𝐾𝐾𝑚𝑚,𝑔𝑔𝑐𝑐𝑔𝑔+[Galactose] (1b) 
The specificity constants for galactose and ATP (kcat/Km,gal and kcat/Km,ATP) 
were estimated directly in Prism as part of the curve-fitting process.  A 
similar method was used for sugars other than galactose. 
 
Analytical methods 
Protein concentrations were estimated by the method of Bradford using 
bovine serum albumin as a standard [28].  The thermal stability of 
galactokinase was measured by differential scanning fluorimetry (DSF) using 
Sypro Orange as the fluorescent probe as previously described [19].  Native 
gel electrophoresis was used to determine the proteins’ resistance to 
chaotropic denaturation as previously described [19, 24]. 
 
Molecular dynamics simulations 
Molecular dynamics (MD) simulations were performed essentially as 
previously described [19, 29].  Chain A from the structure of human 
galactokinase (1WUU; [9]) was prepared by adding Ser230 and Leu231, 
altering selenomethionines to methionine and AMP.PNP to ATP.  RESP 
charges of ligands were calculated using the Gaussian 09 package and 
antechamber present in Amber 10 [30].  Prior to simulation the protein and 
ligands were soaked in a TIP3P solvent box and a maximum distance 
boundary of 8 Å set.  All preparations and simulations were carried out using 
the Amber 10 software package and the Amber Parm 99 forcefield, the 
variants were generated using Biovia Discovery studio [31]. The system was 
neutralised by addition of sodium ions prior to minimisation.  Minimisation 
was carried out using Cartesian restraints and the system subjected to 1250 
cycles of conjugate gradient method followed by 1250 steps of deepest 
decent method at 0.5 kcal mol-1 Å-2 [31b].  The system was then heated from 
0 K to 300 K over 50 ps with a collision frequency of 0.5 ps-1 according to the 
Langevin dynamics method  [32]. Equilibration was carried out at 300 K for 
50 ps using an NVT ensemble.  Production simulations were performed as 
described by [19].  Each simulation was executed for 7 ns at 1 atm and 300 K.  
The timestep was set a 1 fs, the cut off for Van der Waals interactions at 10 
Å, monitored using the particle mesh Ewald method, and the bond lengths 
involving hydrogen atoms were constrained using the SHAKE method [33].  
Molecular dynamics analysis 
The simulations were analysed as described in [19].  Physical characteristics 
of the simulation were monitored using the perl feature in Amber and 
graphs produced using GraphPad prism version 5.03 for windows 
(GraphPad Software, San Diego California USA) (Supplementary Figure S1).  
The ptraj command of Amber was used to perform cluster analysis, 
secondary structure analysis and RMSF calculations.  Structures were 
visualised using Biovia Discovery studio and trajectories in VMD  [34].  The 
timeline feature and normal mode wizards in VMD were used to visualise 
secondary structure and carry out principal component analysis (PCA) 
respectively.  Both methods were carried out on 1 ns of equilibrated 
trajectory, determined by RMSD over time [35]. 
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